Synthra is a company founded in the year 2008.
However, it collects 35 years of experience in the field of targetry, radiopharmaceutical production, quality control and lab automation.
Bruno Nebeling, Synthra's founder and CEO, is considered pioneer of automated production of molecular imaging tracer production.
One of the world's most successful automated synthesizer lines is based on his ideas and developments. Synthra's products are the result of further development of these successful technologies.
Synthra provides products and services for the production of any 11C tracer, e.g. [11C]Methionine, [11C]Choline, [11C]DASP or [11C]Raclopride and any 18F tracer by nucleophilic or electrophilic substitution, e.g. [18F]Dopa, [18F]FDG, [18F]FLT, [18F]Miso, etc…